Antibody Drug Conjugates (ADCS) Market to Jump up to {[Revenue_2028}} by 2028 With Increasing Cancer Patients

Antibody Drug Conjugates (ADCS) Marketwas valued at USD 4.24 Billion in 2021 and is projected to reach {[Revenue_2028}} by 2028, growing at a Compound Annual Growth Rate (CAGR) 18.9% during 2022-2028. Antibody Drug Conjugates (ADCS) are anti-cancer drugs that provide one of the fastest-growing treatments for cancer patients. They have the ability to use specific monoclonal antibodies against targeted antigens to release potentially cytotoxic drugs, with increased activity and reduced toxicity compared to conventional therapies. ADCs use antibodies as a vehicle to deliver molecules of potentially high cytotoxic drugs to certain tumor-related antigens for cancer treatment.

Major factors contributing to the growth of the Antibody Drug Conjugates (ADCS) include an increase in cancer, an increase in the adult population, and an increase in R&D activities for the development of new therapies. However, strict government regulations and high procedural costs, as well as a lack of funding are expected to reverse market growth over the forecast period. In addition, the COVID-19 epidemic has had an impact on the global economy and has shown a significant impact on the operational activities of general non-COVID-19 patient hospitals and the ADC supply chain worldwide.

TheAntibody Drug Conjugates (ADCS) Marketcan be segmented based on drugs, technology, mechanism of action, application, and region. Based on drugs, the market is bifurcated into adcetris and kadcyla. Based on mechanism of action, it is classified into CD30 antibodies and HER2 antibodies. Based on application, the narket is categorized into breast cancer, lymphoma, and others.Initially, breast cancer with HER2 was associated with a higher rate of recurrence and a lower survival rate. The breast cancer segment is expected to respond with the largest market share during the forecast period. The ADC has shown promising results for highly treated disease, CNS metastases, and targeted treatment for breast cancer CD30 and HER2. ADCs consist of a recombinant monoclonal antibody that is slowly bound to a cytotoxic drug or a paid load with a synthetic link, and joins the high antibody exposure for the purpose of cytotoxicity of the chemotherapy drug.

On the basis of regional analysis, the global Antibody Drug Conjugates (ADCS) Market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.Asia Pacific is expected to dominate the global market soon due to the increasing duplication of new technologies. North America is a highly developed region in terms of clinical data, and the use of ADCs is monitored and forms a large part of the established market. In addition, Asia Pacific is expected to play a significant role in market growth during the forecast period.

In April 2021, Pfizer acquired Amply Pharmaceuticals Inc. to conjugate antibody drugs and a few other cancer treatments. Additionally, in March 2021, Pyxis Oncology and Pfizer entered into an agreement to develop and sell two ADCs, PYX-201 and PYX-203, in order to improve survival. Major key companies in the Global Antibody Drug Conjugates (ADCS) Market are Takeda Pharmaceutical Company Ltd. (Japan), F. Hoffmann-La Roche Ltd. (US), Pfizer Inc. (US), AstraZeneca (Sweden), Gilead Sciences Inc. (US), Astellas Pharma (Japan), Seagen Inc. (US), Daiichi Sankyo Company Ltd. (Japan), GlaxoSmithKline PLC (UK), ADC Therapeutics (Switzerland).